New targeted pill aims to shrink lung tumors in patients with common gene mutation

NCT ID NCT06940401

Ongoing Disease control Sponsor: Suzhou Junjing BioSciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests an experimental pill called JS111 in people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the drug is safe and can shrink tumors. Participants take the pill once daily, and the trial will determine the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS111 capsules (AP-L1898)
What this could lead to: If it works, this could offer a new targeted pill for people with a common type of lung cancer that has not been treated yet.
What could go wrong: This is an early-phase trial with only 44 people, so it may not work as hoped. Side effects are possible, and the drug may not control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Show contact details

Locations

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.